Loading, Please Wait...
SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2019.
Third Quarter 2019 highlights:
"During the third quarter, we opened the first Obalon Center for Weight Loss and began to lay the foundation for our new commercial strategy of developing Company-owned retail treatment centers, which we believe will make our proven, FDA-approved gastric balloon weight loss system more accessible to patients,” said William J Plovanic, President and Chief Executive Officer. “Our key accomplishments in the period included creating the required corporate structure, engaging a professional medical corporation to oversee medical care, hiring the necessary staff to run day-to-day operations, entering into the lease and building out the physical space for our first Company-owned retail weight loss treatment center, which resulted in opening the site and initiating first patient treatments.”
Mr. Plovanic continued, “There continues to be strong interest in the Obalon Balloon System from individuals with obesity who are frustrated with not being able to lose weight with diet and exercise-alone and those who are not interested in, or candidates for, surgery. I look forward to providing more detail on our commercial strategy on our earnings call today.”
Revenue for the third quarter of 2019 was $0.3 million, compared to $3.0 million for the third quarter of 2018. The decrease was largely attributable to the Company restructuring its operations, eliminating its direct field sales force in April 2019, and transitioning to its new strategy and business model. Net loss for the third quarter of 2019 was $3.7 million, compared to $6.7 million for the third quarter of 2018. Net loss per share for the third quarter of 2019 was $0.61, compared to $3.47 for the third quarter of 2018.
Cost of revenue was $0.4 million for the third quarter of 2019, down from $1.4 million for the third quarter of 2018. Gross deficit for the third quarter of 2019 was $0.1 million, compared to a gross profit of $1.6 million for the third quarter of 2018.
Research and development expense for the third quarter of 2019 totaled $1.2 million, down from $2.4 million for the third quarter of 2018. Selling, general and administrative expense decreased to $2.5 million for the third quarter of 2019, compared to $5.8 million for the third quarter of 2018.
Operating loss for the third quarter of 2019 was $3.7 million, down from a loss of $6.6 million for the third quarter of 2018.
As of September 30, 2019, the Company had cash and cash equivalents of $19.4 million and no debt.
A conference call to discuss third quarter 2019 financial results is scheduled for today, November 8, 2019, at 9:00 AM Eastern Time (6:00 AM Pacific Time). Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) and using passcode 4987828. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: http://edge.media-server.com/mmc/p/htzhm89b
An archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics, Inc. website located at http://investor.obalon.com in the “News & Events” section.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit http://www.obalon.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Obalon’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to new products and their potential benefits. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Obalon, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that may cause actual results to differ materially from Obalon’s current expectations are more fully described in Obalon’s annual report on Form 10-K for the period ended December 31, 2018, its quarterly report on Form 10-Q for the period ended June 30, 2019 and its other reports, each as filed with the Securities and Exchange Commission. Except as required by law, Obalon assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.
For Obalon Therapeutics, Inc.
President and Chief Executive Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except shares and per share data)
Three Months Ended
Nine Months Ended
|Cost of revenue||412||1,418||2,323||3,919|
|Gross (deficit) profit||(79||)||1,569||171||3,146|
|Research and development||1,174||2,368||5,401||8,359|
|Selling, general and administrative||2,489||5,836||13,025||23,092|
|Total operating expenses||3,663||8,204||18,426||31,451|
|Loss from operations||(3,742||)||(6,635||)||(18,255||)||(28,305||)|
|Interest income (expense), net||37||(70||)||(448||)||(164||)|
|Other expense, net||(1||)||(40||)||(60||)||(155||)|
|Other comprehensive income (loss)||—||(3||)||—||3|
|Net loss and comprehensive loss||$||(3,706||)||$||(6,748||)||$||(18,763||)||$||(28,621||)|
|Net loss per share, basic and diluted||$||(0.61||)||$||(3.47||)||$||(5.07||)||$||(16.05||)|
|Weighted-average common shares outstanding, basic and diluted||6,061,248||1,945,864||3,700,538||1,783,793|
OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except shares and par value data)
|Cash and cash equivalents||$||19,380||$||21,187|
|Accounts receivable, net of allowance of $508 and $665, respectively||238||870|
|Other current assets||683||2,462|
|Total current assets||22,349||28,647|
|Property and equipment, net||1,117||1,739|
|Lease right-of-use assets||1,191||—|
|Liabilities and Stockholders’ Equity|
|Other current liabilities||1,609||1,985|
|Current portion of lease liabilities||557||—|
|Current portion of long-term loan||—||9,930|
|Total current liabilities||3,905||17,231|
|Lease liabilities long-term||687||—|
|Other long-term liabilities||—||48|
|Total long-term liabilities||687||48|
|Commitments and contingencies|
|Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 7,724,100 and 2,351,333 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively||8||2|
|Additional paid-in capital||187,574||161,859|
|Total stockholders’ equity||20,065||13,107|
|Total liabilities and stockholders’ equity||$||24,657||$||30,386|
OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Loss on disposal of fixed assets||128||107|
|Amortization of right-of-use asset||301||—|
|Accretion of investment discount, net||(2||)||(20||)|
|Amortization of debt discount||70||29|
|Change in operating assets and liabilities:|
|Accounts receivable, net||632||1,448|
|Other current assets||1,604||805|
|Lease liabilities, net||(248||)||—|
|Other current and long-term liabilities||(363||)||634|
|Net cash used in operating activities||(17,987||)||(24,017||)|
|Purchases of short-term investments||—||(9,103||)|
|Maturities of short-term investments||2,550||24,302|
|Purchases of property and equipment||(44||)||(867||)|
|Net cash provided by investing activities||2,506||14,332|
|Proceeds from long-term loan||10,000||—|
|Payment on long-term loan||(20,000||)||—|
|Proceeds from issuance of common stock and warrants, net of paid issuance costs||15,014||9,973|
|Proceeds from issuance of common stock, net of issuance costs||8,659||—|
|Proceeds from stock issued under employee stock purchase plan||—||148|
|Proceeds from sale of common stock upon exercise of stock options||1||38|
|Fees paid in connection with loan amendment||—||(30||)|
|Net cash provided by financing activities||13,674||10,129|
|Net (decrease) increase in cash and cash equivalents||(1,807||)||444|
|Cash and cash equivalents at beginning of period||21,187||21,108|
|Cash and cash equivalents at end of period||$||19,380||$||21,552|
|Supplemental cash flow information:|
|Unpaid issuance costs||$||295||$||160|
|Property and equipment in accounts payable||$||—||$||106|